Evofem Biosciences, Inc. has announced that the holders of a majority of its Series E-1 Preferred Stock have approved amendments to the company's Certificate of Designations. The approved changes will increase the total authorized shares from 2,300 to 10,000 to facilitate the payment of dividends "in kind" using additional shares of Preferred Stock and update certain definitions. The decision was also approved by the company's Board of Directors.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-018412), on July 09, 2025, and is solely responsible for the information contained therein.